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THE objective of this study was to determine
whether arachidonate metabolites are involved in
the vasoconstrictive effects of angiotensin H in
rats. In the isolated perfused heart, dexa-
methasone (4mg/kg) significantly suppressed the
maximal decreases in coronary flow induced by
angiotensin H and vasopressin (reference drug).
In the heart, the nonselective lipoxygenase inhi-
bitor nordihydroguaiaretic acid (NDGA, IM)
markedly suppressed the angiotensin H-induced
decreases in coronary flow. NDGA (10M) inhib-
ited both angiotensin H- and methoxamine-
(reference drug) induced contractions in aortic
rings with (in the presence of L-NAME) and
without endotheHum. In the heart, the leuko-
triene synthesis inhibitor MK-886 (0.3M) sig-
nificantly reduced the maximal effects to
angiotensin H, but the leukotriene antagonist FPL
55712 (0.1 and 0.3M) had no effect. We conclude
that in the isolated perfused rat heart angiotensin
H-induced decreases in coronary flow are in part
mediated by Hpoxygenase products, which might
be derived from the 5-Hpoxygenase pathway, but
are probably not leukotrienes. Furthermore,
endotheHum independent Hpoxygenase products
mediate part of the contractile responses to
angiotensin H in the isolated rat aorta.
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Introduction
Vascular angiotensin II is involved in the long-
term regulation of blood vessel function and
structure and is a major pathophysiological factor
in hypertension, atherosclerosis and restenosis.
There is accumulating evidence for the presence
of a complete renin-angiotensin system in the
heart, and a functional role has been sug-
gested.
2-5 Locally generated angiotensin II could
be of importance in the regulation of coronary
flow, as has for instance been demonstrated in
patients with microvascular angina (Syndrome
X).6 Furthermore, angiotensin II has a direct
effect on protein synthesis, which contributes to
cardiac hypertrophy.
7
It is well known that angiotensin II exerts its
effects through stimulation of inositol phospholi-
pid metabolism. Angiotensin II activates phos-
pholipase C, which hydrolyses phospha-
tidylinositol biphosphate into inositol triphos-
phate and 1,2-diacylglycerol.
8 In addition, it has
been demonstrated recently that 12-1ipoxygenase
activation plays a key role in, e.g. angiotensin II-
induced vascular smooth muscle cell hyper-
trophy.9 Other studies have shown that arachido-
nate metabolites contribute to various responses
to angiotensin II, including inflammatory, con-
tractile and secretory actions,m-6 This paper
deals with the contribution of arachidonate meta-
bolites to the vasoconstrictive effect of angioten-
sin II in the coronary circulation and aorta of the
rat. If arachidonate metabolites play a role in
coronary constrictions evoked by angiotensin II,
it could be hypothesized that drugs inhibiting
arachidonate metabolism have a beneficial effect
in the prevention of angiotensin II-induced vaso-
spasms, that can lead to angina pectoris or
hypertension. To assess the contribution of ara-
chidonate metabolites to angiotensin II-induced
responses, we tested several drugs that interfere
with arachidonate metabolites in isolated Langen-
dorff perfused rat hearts and isolated aortas. To
study whether arachidonate dependent effects
were selective for angiotensin II we also tested
methoxamine and vasopressin as agonists, which
like angiotensin II exert their effects through sti-
mulation of inositol phospholipid metabolism.
We examined the cyclo-oxygenase pathway in
the effects of angiotensin II by using the cyclo-
oxygenase inhibitor indomethacin, the lipoxy-
genase pathway was studied by using the non-
selective lipoxygenase (and cyclo-oxygenase)
inhibitor nordihydroguaiaretic acid (NDGA), the
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corporeal flowsensor (Skalar Medical, Delft, the
Netherlands) and recorded on a Gould recorder.
In the heart, left ventricular pressure was meas-
ured by a water filled balloon (HSE, Freiburg,
Germany) and recorded on a Gould recorder.
The diastolic left ventricular pressure was adjus-
ted between 5 and 10mm Hg. The heart was -
|,- electrically driven at a frequency of 5Hz (32C)
AA861 and equilibrated for 30 min. The experiments
were performed at 32C, since at 37C some
P ETE 15-H(P)ETE hearts escape pacing. After equilibration, dose-
response curves were obtained with vasopressin
FPL 8S712 > leuRotriene$ (10-15 10
-8 moles) and angiotensin II (10-6
10-s moles). The agonists (0.1 ml bolus injec- FIG. 1. Scheme of metabolism of arachidonic acid via the cyclo- tions) were administered directly into the p ’er ’- oxygenase and lipoxygenase pathway. Enzyme inhibitors are
given in bold type. NDGA, nordihydroguaiaretic acid; PGs, pros- sion stream just proximal to the heart. After each
taglandins; TxA2, thromboxane A2; H(P)ETE, hydro(pero)- dose a stable new baseline was reached before
xyeicosatetraenoic acid. The leukotriene antagonist FPL 55712
is underlined, the next dose was given.
5-1ipoxygenase inhibitor 2,3,4,5-tri-methyl-6-(12-
hydroxy-5,10-dodecadiynyl)-1,4-ben-zoquinone
(AA 861), the leukotriene synthesis inhibitor 3-[ 1-
(p-chlorobenzyl)-5-(isopropyl)-3-tert-butylthioin-
dol-2-yl]-2,2-dimethylpropanoic acid (MK-886)
and the leukotriene antagonist sodium 7-[3-(4-
acetyl-3-hydroxy-2-pro-pylphenoxy)-2-hydroxy-
propoxy] -4-oxo-8-propyl-4H-1-benzopyran-2-
carboxylate (FPL 55712). Further-more, dexa-
methasone was used to inhibit the production of
arachidonic acid via the phospholipase A2
pathway (Fig. 1). Losartan (DuP 753) was used
to determine whether the angiotensin II-induced
effects were mediated by the angiotensin II
receptor subtype-1. In addition, to study the
origin of arachidonate metabolites, we performed
experiments in the aorta in the presence (with
the nitric oxide synthase inhibitor N6-nitro-L-argi
nine methyl ester (L-NAME)) and absence of
endothelium.
Materials and Methods
Preparation of aortic rings.. The thoracic aorta
was rapidly excised and immersed in Krebs-
Ringer solution of the following composition
(mM): NaCl, 118; KCl, 5.9; mgSO4.7H20, 1.2;
CaC12.2H20, 2.5; NaHiPO4.H20, 1.2; NaHCO3,
24.9; CaiEDTA, 0.026; and glucose 11.1
(pH 7.4). After cleaning the aorta from fat and
connective tissue, it was cut into rings of 2-3mm
length. In some tings, the endothelial layer was
removed by inserting the tip of a forceps in the
lumen of the rings and gently rolling the tings on
moistened filter paper. The rings were sus-
pended between two stirrups in 10ml organ
chambers filled with oxygenated (95% O2/59/o
CO2) Krebs-Ringer solution. The temperature
was maintained at 37C. Changes in force were
measured with an isometric force transducer
(Harvard Bioscience) and recorded by computer.
The aortic rings were set at an initial resting
tension of 2g. After 60 min of equilibration,
during which the Krebs-Ringer solution was
replaced every 15 min, the tings were challenged
twice with 100mM KC1, with an interval of 35
min, wherein the resting tensions were read.
Animals: In this study we used 196 male Wistar justed to 2 g. The absence of endothelium was
rats (180-260g). Food and water were allowed confirmed by the lack of acetylcholine (1 l.tm)
ad libitum. After heparinization (1000IU/kg i.p.) induced relaxations in rings precontracted with
rats were killed by decapitation. 0.1 l.tM phenylephrine.
Perfusion of the isolated heart.. The heart of each Aorta experiments.. Cumulative concentration-
rat was rapidly excised and immediately mounted response curves for angiotensin II (0.1-100nM)
for perfusion by the Langendorff technique, and methoxamine (0.01-1001.tM) were con-
using constant pressure of 80cm water. The structed in aortic rings with and without endo-
perfusion fluid was Krebs-Ringer (pH 7.4) thelium after 30 min of incubation with 0.1%
containing (expressed as mM) NaC1, 128; KCl, ethanol, NDGA (1, 3 or 10 l.tM), AA 861 (101.tM)
4.7; MgCI2, 0.6; NaHiPO4, 0.4; NaHCO3, 27; or after incubation with 101.tM indomethacin
CaCl2, 1.3; and glucose 11. The Krebs-Ringer (part of the Krebs-Ringer solution). The experi-
solution was kept at 32C and equilibrated with ments with 0.1% ethanol and NDGA (3 and
95% O2 and 5% CO2 throughout the experiment. 101.tM) were also performed with vasopressin
Coronary flow was measured with an extra- (1-1000 nM).
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Experiments with endothelium were con- equilibration time of 30 min and during the con-
ducted with and without 100 l.tM L-NAME added struction of the dose-response curves. One
to the incubation medium, dose-response curve was constructed per heart
Finally, concentration-response curves for in all treatment and control groups.
angiotensin II (0.1-1000nM) were constructed
after 30 min of incubation with losartan (0.01, Data analysis:
0.1 and 1 laM) in aortic rings with endothelium in
the presence of lO01.tM L-NAME or in tings
without endothelium.
Drugs and drug solutions.. Angiotensin II (acetate
salt), indomethacin, NDGA, methoxamine HCl,
phenylephrine HCl, acetylcholine HCl, L-NAME
and sodium nitroprusside (SNP) were obtained
from Sigma Chemical (St. Louis, MO, USA). AA
861 (2,3,4,5-trimethyl-6-(12-hydroxy-5,10-dodeca-
diynyl)-l,4-benzoquinone) was obtained from
Takeda Chem. Ind. Ltd. (Osaka, Japan). Losartan
(DuP 753) was a gift from du Pont de Nemours
& Company (Wilmington, Del., USA). Heparin
was from Leo (Weesp, the Netherlands) and
sodium pentobarbitone was from Ceva. (Paris,
Heart. When baseline coronary flow was sig-
nificantly enhanced by drugs (NDGA, AA 861,
MK-886 or FPL 55712), we used control groups
with SNP in sufficient concentration to reach a
baseline coronary flow that was equal to the
baseline coronary flow in the drag groups. These
control groups with SNP were added to exclude
the possibility that the enhancing effects of the
drugs on baseline coronary flow might obscure
the possible effects of these drugs on angio-
tensin II-induced constrictions. Baseline coronary
flow values were analysed by Student’s t-test or
ANOVA followed by Duncan’s Range Test for
multiple comparison.
Coronary vasoconstriction induced by angio-
tensin II and vasopressin is expressed as the per- France). Vasopressin (Vasopressin-Sandoz:
lypressin) was a gift from Sandoz, Wander centage reduction of baseline coronary flow.
Pharma (Uden, the Netherlands). FPL 55712 Dose-response curves of angiotensin II and vaso-
(sodium 7-[3-(4-acetyl-3-hydroxy-2-propylphe- pressin were analysed by MANOVA with a
noxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-l-b- repeated measures design.
enzopyran-2-carboxylate) was a gift from Fisons Aorta. Contractions are expressed as percentage
Pharmaceuticals (Loughborough, England). MK- of the maximal contraction of 100mM KCl. Con-
886 was a gift from Merck Frosst (Quebec, centration-response curves for angiotensin II,
Canada) and dexamethasone phosphate (deca- methoxamine and vasopressin were analysed by
dron) was obtained from O.P.G. (Utrecht, the MANOVA using a repeated measures design.
Netherlands). All other chemicals were of analy- Heart and aorta. A p-value < 0.05 was con- tical grade (Merck, Darmstadt, Germany). sidered statistically significant. Data are expressed Unless otherwise specified, drugs were dis- as means + S.E.M. In the figures, a significant solved in saline. Dexamethasone phosphate difference-between the entire dose/concen- (4mg/kg) and saline (2ml/kg) were adminis- tration-response curves is indicated with an tered into the tail vein 5.5h prior to testing, asterisk. NDGA, AA 861, and MK-886 were dissolved in
ethanol. For the aorta experiments NDGA and
AA 861 were diluted with saline (final concentra- Rult
tion ethanol, < 0.1%). For the heart experiments
NDGA, AA 861 and MK-886 were diluted to the Isolated Langendorffperfused heart:
appropriate concentration in the perfusion fluid
(final concentration ethanol, <0.005%). FPL
55712, SNP and losartan were dissolved in bidis-
tilled water and diluted to the appropriate con-
centration in the perfusion fluid. Indomethacin
was dissolved in 4.54% NaHCO and then added
to the Krebs-Ringer solution (final concentration
Baseline values. Baseline coronary flow values
for all groups are shown in Table 1. Since
NDGA, AA 861, MK-886 and FPL 55712 enhanced
baseline coronary flow, control groups were
used with SNP O.01-O.031.tM to reach a similar
baseline coronary flow.
NaHCO. heart, 27mM; aorta, 24.9mM). Vaso- Angiotensin II and vasopressin effects. Angio-
pressin was diluted with saline. Solutions were tensin II induced a dose-dependent decrease in
freshly prepared every day and kept on ice and coronary flow with a pD2 of 11.5 4-0.1 and an
protected from light. Emax of 55.9 4- 2.4% (n 8) (Fig. 2). Losartan
In experiments using isolated hearts, NDGA, (0.01-101.tM) reduced the angiotensin II-induced
AA 861, MK-886, FPL 55712, SNP, losartan (and decreases in coronary flow in a concentration
indomethacin) were already present in the perfu- dependent manner. The effect of losartan 10-5M
sion fluid before mounting the hearts, during the on the response to angiotensin II is shown in
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Table 1. Baseline coronary flow (CF) and left ventricular pressure (LVP) values
n CF (ml/min) LVP (mmHg)
Angiotensin II
Control: Krebs-Ringer 8
Losartan 10 IM 8
Indomethacin 10 IM 7
Saline 2 ml/kg -5.5h 5
Dexamethasone 4mg/kg -5.5h 5
Control: SNP 0.01 IM 7
NDGA M 8
MK-886 0.3 IM 5
FPL 55712 0.11M 8
FPL 55712 O.31M 8
Control: SNP 0.03 laM
AA861 5M
AA 861 5 IM and indomethacin 10
Vasopressin
Control: Krebs-Ringer
Saline 2ml/kg -5.5h
Dexamethasone 4mg/kg -5.5 h
5.7 +__ 0.3 77.1 __+ 7.1
5.8 _____
0.6 74.5 _____
4.6
6.4 _____
0.5 73.1 _____
4.9
6.9 _____
0.2 66.6 ____. 5.6
6.8 _____
0.3 81.0 _____
6.4
7.7 __+ 0.5 82.1 __+ 3.1
7.2 +__ 0.2 74.1 +___ 4.8
7.7 -I- 0.1 69.2 _____
8.7
7.0 -t- 0.3 71.9 -i- 4.0
6.9 -t- 0.2 67.5 _____
7.0
6 8.5 __+ 0.3 65.3 __+ 5.6
8 8.6 _____
0.6 55.9 -I- 5.3
6 8.3 ____. 0.3 45.8 _____
3.9*
6 6.0 __+ 0.2 88.5 __+ 2.3
6 5.8 -t- 0.3 65.5 -t-__ 4.8
6 6.3 _____
0.5 86.5 ___+ 2.0*
Control: SNP 0.011M 8 8.0 ___
0.4 87.4 -i- 3.2
NDGA IM 8 7.2 +_ O. 77.9 -I- 2.7*
AA 861 5 IM 8 7.9 _+ 0.2 63.6 -t- 5.2*
MK-886 0.3 IM 5 8.3 -/-_ O. 83.8 -t- 3.8
Drug groups were compared with their respective control (e.g. indomethacin vs. Krebs-Ringer, NDGA
IM vs. SNP 0.01 IM and dexamethasone vs. saline pretreatment). *significant (p < 0.05) difference
between drug(s) and respective control (Krebs-Rnger, SNP 0.01 IM, SNP 0.03 IM or saline 2 ml/kg,
--5.5 h).
Fig. 2. The pA2 value calculated for losartan in
the isolated perfused heart was 8.5. Also with
vasopressin a dose-dependent decrease in cor-
onary flow was observed that was larger than for
angiotensin II (pD2, 10.0 0.1; Emax,
74.2_ 5.1%) (data not shown). The effect of
angiotensin II on left ventricular pressure was
marginal, whereas the left ventricular pressure
was decreased at high vasopressin concentrations
(1 and 10nM) (data not shown).
LL -20
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FIG. 2. Effects of bolus injections of angiotensin II (All) on cor-
onary flow (CF) in isolated perfused rat hearts in the absence
((C)) and presence of 10IM Iosartan (A) or 10 IM indomethacin
(O). Results are means _+. S.E.M. of six to eight experiments.
Modulation by dexamethasone. After pretreat-
ment with 4mg/kg dexamethasone for 5.5 h, the
maximal angiotensin II- and vasopressin-induced
reductions in coronary flow were significantly
reduced from 53.7 ___
3.8% (n 5, saline pre-
treated rats) to 40.5 3.6% (n 5; Fig. 3, left
panel) and from 74.9 +_ 7.2% (n 6, saline pre-
treated rats) to 57.5 3.6% (n 6; Fig. 3, right
panel), respectively.
Modulation by indomethacin, NDGA and AA
86I. Indomethacin (101.tM) did not affect the
flow reduction by angiotensin II (pD2,
11.1 0.1; Emax, 49.1 3.7%, n 7, N.S.)
(Fig. 2). NDGA (1 l.tM) significantly reduced the
maximal constriction to angiotensin II from
48.4 _+ 3.1% (n 7) to 23.9 2.6% (n 8;
Fig. 4, left panel). NDGA (1 l.tM) also had a sig-
nifican inhibitory effect on the responses to
vasopressin (Fig. 4, right panel).
The 5-1ipoxygenase inhibitor AA 861 (51.tM)
did not significantly reduce the responses to
angiotensin II (Fig. 5, left panel) and vasopressin
(Fig. 5, right panel) (angiotensin II, 30nM SNP;
vasopressin, 10nM SNP). To test whether indo-
methacin induced shunting of arachidonate meta-
bolism through the lipoxygenase pathway, we
combined indomethacin with AA 861. The com-
bination of AA 861 (5t.tM) and indomethacin
(101M) significantly reduced maximal angioten-
sin II-induced constrictions from 42.9 +__ 3.8%
(n=6; control, 30nM SNP) to 22.3_ 3.4%
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FIG. 3. Effects of bolus injections of angiotensin II (All, left panel)
and vasopressin (VASO, right panel) on coronary flow (CF) in iso-
lated perfused rat hearts after pretreatment with saline (2 ml/kg)
(O) or dexamethasone 4mg/kg (O) 5.5h prior to testing.
Results are means -I- S.E.M. of five to six experiments. Asterisks
indicate significant (p < 0.05) difference between curves.
(n 6; Fig. 5, left panel). No effect of ethanol
0.005% was observed on angiotensin II-induced
reductions in coronary flow (data not shown).
Modulation by MK-886 and FPL 55712. Pretreat-
ment with 0.3 l.tM MK-886 had a significant inhi-
bitory effect on the maximal angiotensin II-
induced decreases in coronary flow (Fig. 6, left
panel), but not on the vasopressin-induced
decreases in coronary flow compared to the
0.01 j.tM SNP control group (Fig. 6, right panel).
FPL 55712 (0.1 and 0.3 l.tM) had no effect on the
angiotensin II-induced decreases in coronary flow
(Fig. 6, left panel).
Isolated aorta:
Effects of NDGA on angiotensin II-, methox-
amine-, and vasopressin-induced contractions in
aortic rings without endothelium. In the pre-
sence of 0.19/o ethanol, angiotensin II induced
0
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O
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FIG. 5. Effects of bolus injections of angiotensin II (All, left panel)
and vasopressin (VASO, right panel) on coronary flow (CF) in iso-
lated perfused rat hearts in the presence of 30nM (left panel),
100nM (right panel) sodium nitroprusside ((C)), 5 IM AA 861
(O) or the combination of 5 IM AA 861 and 101M indometha-
cin (A). Results are means -I- S.E.M. of six to eight experiments.
Asterisk indicates significant (p<0.05) difference between
drugs and SNP.
concentration dependent contractions in aortic
rings without endothelium (Fig. 7a). The
maximal contractions induced by angiotensin II
were inhibited by 3 and 10 t.tM NDGA in a con-
centration dependent manner. Pretreatment with
10 l.tM NDGA caused a significant depression of
the contractions to angiotensin II compared to
control: Emax, 61.3 _
12.4% (n 6) and
157.5 6.8% (n 6), respectively (Fig. 7a). For
methoxamine-induced contractions the maximal
effect was only slightly reduced by NDGA (from
175.3 -t- 5.3% (n 6) to 145.9 9.3% (n 7)),
while a pronounced rightward shift of the con-
centration-response curve was observed
(Fig. 7b). The vasopressin response curve was
less pronounced shifted to the right by NDGA
than that of methoxamine, and like methoxamine
o -20
.E
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FIG. 4. Effects of bolus injections of angiotensin II (All, left panel)
and vasopressin (VASO, right panel) on coronary flow (CF) in iso-
lated perfused rat hearts in the presence of 0.01 IM sodium
nitroprusside ((C)) or IM NDGA (). Results are means ___
S.E.M. of seven to eight experiments. Asterisks indicate sig-
nificant (p < 0.05) difference between drug and SNP.
-40
-80
T
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FIG. 6. Effects of bolus injections of angiotensin II (All, left panel)
and vasopressin (VASO, right panel) on coronary flow (CF) in iso-
lated perfused rat hearts in the presence of 0.01 IM sodium
nitroprusside ((C)), 0.11M FPL 55712 (), 0.31M FPL 55712
(,) or 0.3 IM MK-886 (.). Results are means __+ S.E.M. of five
to eight experiments. Asterisk indicates significant (p < 0.05) dif-
ference between drug and SNP.
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FIG. 7. Concentration-response curves of angiotensin II (All) (a),
methoxamine (b) and vasopressin (VASO) (c) in the isolated rat
aorta in the absence of endothelium after incubation for 30 min
with ethanol 0.1% (O), pM NDGA (1), 31M NDGA (A) or
IOIM NDGA (,). Results are means ___
S.E.M. of six to seven
experiments. The asterisks indicate significant (p < 0.05) differ-
ence between NDGA and ethanol pretreated aortic rings.
there was no change in maximal effect (Fig. 7c).
The lipoxygenase inhibitor had no effect on the
baseline tension of these rings (data not shown).
Effects of indomethacin and AA 86I on angio-
tensin II-, and methoxamine-induced contrac-
tions in aortic rings without endothelium. AA
861 (10 btM) and indomethacin (10 l.tM) had no
effect on the contractile responses to both angio-
tensin II and methoxamine (Table 2).
Effects ofNDGA on angiotensin II-, and methox-
amine-induced contractions in aortic rings with
endothelium in the presence of L-NAME. In this
set of experiments, angiotensin II and methox-
amine induced concentration dependent contrac-
tions in aortic rings with endothelium with a
maximum of 78.0 ___
9.9% (eleven rings, six rats)
and 199.0 __+ 10.4% (eleven rings, six rats)
respectively (Fig. 8, left" panels).
t-NAME 100 l.tM significantly increased the con-
tractions to angiotensin II (maximum,
187.8 ___
12.2%, eleven rings, six rats) and
methoxamine (maximum, 209.4 _+ 9.5%, twelve
rings, six rats) (Fig. 8, left panels).
In the presence of -NAME a second concen-
tration-response curve was constructed for
angiotensin II and methoxamine after incubation
with either 0.1% ethanol (control) or 10M
NDGA. In contrast to methoxamine, the maximal
effect to angiotensin II of the second concentra-
tion-response curve was significantly lower com-
pared to the first concentration-response curve.
The lipoxygenase inhibitor significantly attenu-
ated the maximal contraction to angiotensin II
and shifted the concentration-response curve of
methoxamine to the right (Fig. 8, right panels).
Effects of losartan on angiotensin II-induced
contractions in aortic rings without endothelium
and with endothelium in the presence of L-
NAME. Incubation of denuded aortic rings with
losartan (10 nM, 100nM and 1 M) shifted the
concentration-response curve to angiotensin II
to the right in a concentration dependent
manner. With the highest concentration of losar-
tan (1 btM) the angiotensin II-induced contrac-
tions (up to 300nM angiotensin II) were virtually
abolished. Similar effects were seen in intact
aortic rings in the presence of 100 l.tM t-NAME
(data not shown). The pAi-value calculated for
losartan in rat aorta (with and without endothe-
lium) was 8.2.
Discussion
The objective of this study was to determine
whether arachidonate metabolites play a role in
the vascular effects of angiotensin II in rats.
Table 2. Effect of 101M AA 861 and 10pM indomethacin (INDO) on angiotensin II and methoxamine
induced contractions in aortic rings without endothelium
Angiotensin II Methoxamine
pD2 Emax (%) pD2 Emax (%)
Saline 8.76 -t- 0.03 (5) 192.2 -I- 10.5 (5) 6.25 ___
0.04 (5) 215.6 ___
16.9 (5)
AA 861 8.84 -i- 0.19 (5) 175.4 ___
11.1 (5) 6.35 ___
0.07 (6) 201.7 -t- 9.0 (6)
INDO 8.50 -i- 0.12 (5) 153.2 ___
22.3 (5) 6.23 __+ 0.08 (6) 189.8 ___
5.3 (6)
Between brackets, number of experiments.
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(minimal) contribution of the AT2-receptor to
the effects of angiotensin II. The pA2 value of
losartan in the heart and aorta was 8.5 and 8.2
respectively. These values are similar to pA2
values reported for losartan in various tissues of
a number of species (e.g. rabbit aorta, rat portal
vein)
8 indicating that the receptor for angioten-
sin II in these tissues is the same.
Several studies have demonstrated that arachi-
donate metabolites of the lipoxygenase pathway
participate in angiotensin II dependent mecha-
nisms, e.g. angiotensin II-induced release of neu-
trophil chemoattractant substance,m angiotensin
II-induced stimulation of aldosterone secre-
tion,’2 angiotensin II-induced inhibition of
renin release, angiotensin II-induced vasocon-
striction5’6’9 and angiotensin II-induced stimu-
lation of cell growth.9’’2
In this study, pretreatment of rats with 4 mg/kg
dexamethasone 5.5 h prior to testing, significantly
suppressed the maximal decreases in coronary
flow to angiotensin II and vasopressin. Glucocor-
ticoids like dexamethasone stimulate the synthe-
sis of proteins that inhibit phospholipase A2, and
Methoxamine (btM) Methoxamine (pM) thus block one of the major enzymes that release
FIG. 8. Concentration-response curves of angiotensin II (All) arachidonic acid from the phospholipid pools.
2
(upper panels) and methoxamine (lower panels)in the isolated The effect of dexamethasone on angiotensin II
rat aorta in the presence of endothelium. Left panels: first con-
centration-response curves after incubation for 30 min with and vasopressin induced decreases in coronary
saline (O) or 100 I.tM L-NAME (O). Right panels: second con- flow suggests that arachidonate metabolites are
centration-response curves after incubation for 30 min with involved in both angiotensin II and vasopressin- 100M L-NAME and 0.1% ethanol (A) or IO0M L-NAME and
101M NDGA (,). Results are means -t- S.E.M. of ten to twelve induced constrictions.
rings of six rats (experiments). The asterisks indicate significant NDGA had a marked inhibitory effect on the
(p < 0.05) difference between curves, angiotensin II-induced decreases in coronary
flow and inhibited the angiotensin II-induced
From our results we can conclude that: (1) in contractions in the aorta in a concentration
the coronary system of the rat, part of the anglo- dependent manner, while the cyclo-oxygenase
tensin II-induced decreases in coronary flow are inhibitor indomethacin had no effect in both
mediated by lipoxygenase products and not by tissues. NDGA, which is known to be a dual
cyclo-oxygenase products; (2) these lipoxygenase cyclo-oxygenase and lipoxygenase inhibitor
22 as
products might be derived from the 5-1ipoxy- well as an anti-oxidant, has been reported to
genase pathway of arachidonate metabolism but have various nonspecific effects. Inhibition of
are probably not leukotrienes; and (3) endothe- endothelium-dependent relaxations2 and of
lium independent lipoxygenase products (not kinin and noradrenaline-induced contractions,
24
cyclo-oxygenase products) mediate part of the possibly related to the inhibition of the trans-
contractile responses to angiotensin II and to a membrane calcium influx,
25 have been described.
lesser extent to methoxamine and vasopressin in However, based on our results we have reason
the isolated rat aorta, to believe that lipoxygenase products (not cyclo-
In the isolated perfused heart and aorta, angio- oxygenase products) mediate at least part of the
tensin II acted via the AT1 receptor as was shown angiotensin II-induced constrictions, since in the
by the inhibition by losartan.
8 We found that heart several inhibitors acting at different levels
losartan reduced the angiotensin II-induced of the arachidonate metabolism (NDGA, dexa-
decreases in coronary flow and angiotensin II- methasone, MK-886) significantly reduced angio-
induced contractions in the aorta, in a concentra- tensin II-induced decreases in coronary flow.
tion dependent manner. In the presence of losar- Furthermore, we have shown that NDGA inhib-
tan 10-5 M, the angiotensin II effect is almost ited the contractions to angiotensin II in a con-
abolished in the heart. However, we did not centration dependent manner in the aorta.
perform experiments with a specific AT2-receptor The exact lipoxygenase pathway (5-, 12-, or
antagonist and therefore cannot exclude a 15-1ipoxygenase) cannot be determined from our
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results. The leukotriene synthesis inhibitor MK- aorta were also attenuated by NDGA; however, to
886 significantly reduced the maximal decrease a much lesser extent compared to angiotensin II.
in coronary flow induced by angiotensin II in the Therefore, for vasopressin and methoxamine,
heart. In contrast, in both aorta and heart, the 5- lipoxygenase products may also be involved in
lipoxygenase inhibitor AA 861 had no effect on (coronary) constrictions. The effects of angioten-
the responses to angiotensin II. MK-886 inhibits sin II in aortic rings (denuded) were character-
the membrane translocation of 5-1ipoxygenase by ized by a marked reduction of the maximal
an interaction with the 5-1ipoxygenase activating effect, while for inhibition of the methoxamine
protein and subsequently prevents the activation and vasopressin contractions a rightward shift of
of 5-1ipoxygenase.
228 MK-886 is selective for the the concentration-response curve was observed
5-1ipoxygenase pathway of arachidonate acid and no effect or a minor effect on the maximal
metabolism since it has no effect on 12-1ipoxy- contractions was seen. In accordance with our
genase or cyclo-oxygenase,
26 whereas AA 861 can results are observations in aorta strips of the
also inhibit 12-hydroxyeicosatetraenoic acid (12- rabbit where 10btM NDGA caused a 10% depres-
HETE) formation.29 On the basis of the selectiv- sion of the noradrenaline-induced tension and
ity of MK-886, we suggest that the 5-1ipoxygenase AA 861 (up to 30 tM) had no effect.24 Others
pathway is the candidate that most likely med- have demonstrated that the constrictor response
iates decreases in coronary flow induced by to a maximal concentration of norepinephrine
angiotensin II. was not affected by the lipoxygenase inhibitor
The leukotriene antagonist FPL 55712 did not baicaleine,
6 and this is compatible with our
change the angiotensin II-induced decreases in results. Additional studies are required to deter-
coronary flow, indicating that the end products mine whether the different profiles of NDGA
from the 5-1ipoxygenase pathway, the leuko- inhibition for angiotensin II and methoxamine/
trienes, are not involved in angiotensin II-induced vasopressin are related to differences in mechan-
decreases in coronary flow, leaving 5-hydroper- ism of action of the agonists. It has been shown
oxyeicosatetraenoic acid (5-HPETE) and 5-hy- that 10M NDGA inhibits the stimulated influx
droxyeicosatetraenoic acid (5-HETE)as potential of extracellular calcium in rabbit neutrophils,
mediators of the angiotensin II-induced effects in without affecting cellular calcium redistribution.25
the isolated perfused rat heart. This may contribute to the inhibitory action by
Saito et al. also suggested that in cultured rat NDGA at 10/.tM on agonist-induced arterial con-
vascular smooth muscle cells angiotensin II traction. In rat aortic rings, however, we already
induced constrictions are mediated by H(P)ETEs. observed an inhibitory effect of NDGA at 3 tM.
However, in contrast with our results and in NDGA (10 tM) inhibited both angiotensin II-
accordance with those of other investigators with and methoxamine-induced contractions in aortic
respect to smooth muscle cell growth’ and ster- rings with (in the presence of >NAME) and
oidogenesis,’4 Saito et aL emphasized the without endothelium, indicating that lipoxygenase
role of 12H(P)ETE. Further studies are necessary products that mediate angiotensin II- and
to determine which of these two pathways, the methoxamine-induced contractions do not origi-
5-, or the 12-1ipoxygenase pathway is predomi- nate from the endothelium.
nant under specified conditions. NDGA, AA 861, MK-886 and FPL 55712
Indomethacin alone had no effect on angioten- induced a significant increase in baseline coro-
sin II-induced constrictions in both aorta and nary flow suggesting that rat coronary flow is
heart. The lack of effect for indomethacin on controlled in part by endogenously produced
angiotensin II-induced contractions in rat aorta leukotrienes and perhaps other lipoxygenase
was also shown in other studies.3 However, in products. In accordance, several investigators
the presence of AA 861 we observed a marked have found that AA 861, FPL 55712 and NDGA
inhibitory effect of indomethacin on angiotensin increased baseline coronary flow in perfused rat
II-induced effects in the isolated perfused heart, and guinea pig hearts.33’34 A role for cyclo-oxyge-
In guinea-pig hearts indomethacin induced shunt- nase products in the regulation of rat coronary
ing of the arachidonate metabolism through the flow is not likely, since indomethacin did not
lipoxygenase pathway.32 Such a mechanism affect baseline coronary flow in rats. We used
might enhance the synthesis of lipoxygenase pro- control groups with SNP in sufficient concentra-
ducts leading to e.g. 5-HPETEs or 5-HETEs when tion to reach a baseline coronary flow that was
indomethacin is present, equal to the baseline coronary flow in the drug
The inhibitory effect of NDGA was not selec- groups. To our knowledge none of the reported
tive for angiotensin II. Vasopressin-induced arachidonic acid metabolites operate through the
decreases in coronary flow and methoxamine- same mechanism as SNP, i.e. elevation of cGMP
and vasopressin-induced contractions in the production. In addition, we performed some
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pilot experiments with NDGA in the presence of
10nM SNP. In those experiments the angiotensin
II-induced decreases in CF were not significantly
different from the decreases in CF in the pre-
sence of NDGA alone, indicating that SNP did
not interfere with the effect of NDGA.
In summary, lipoxygenase products and not
cyclo-oxygenase products mediate at least part of
the angiotensin II-induced decreases in coronary
flow in the isolated perfused heart of the rat.
These products also play a small role in the con-
strictions to vasopressin in the isolated rat heart.
The lipoxygenase products involved in the
effects of angiotensin II might be derived from
the 5-1ipoxygenase pathway of arachidonate
metabolism but are probably not leukotrienes.
Furthermore, endothelium independent lipoxy-
genase products (not cyclo-oxygenase products)
mediate part of the contractile responses to
angiotensin II and to a lesser extent to methox-
amine and vasopressin in the isolated rat aorta.
Therefore, we can conclude that intermediary
(endothelium-independent) lipoxygenase pro-
ducts other than leukotrienes play a role in the
vascular effects of angiotensin II in the rat.
Experiments with 5-HPETE and/or 5-HETE to
study whether the effects of these mediators are
comparable with those of angiotensin II are an
interesting subject for further investigation.
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